Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.55 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8538004 | 1.00 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL8539590 | 1.00 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL6814907 | 1.00 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL4972231 | 1.00 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL7392856 | 0.90 | KLK5 (0.67) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL10788604 | 0.90 | KLK5 (0.64) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL12751287 | 0.89 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL13328536 | 0.89 | KLK5 (0.66) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL14209635 | 0.89 | KLK5 (0.55) | KLK5ATMPSEN1PSEN2APH1B | |
| SCHEMBL5861336 | 0.89 | KLK5 (0.61) | KLK5ATMPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730669-B2 | PROPHYLACTICALLY PREVENTING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, AND TREATMENT OF A RETROVIRAL INFECTION | G. D. SEARLE & CO. | 2004-05-04 | — | — | US | disclosed |
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | KLK5 2113/4885ATM 3610/4885PSEN1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.